EVALUATION OF DAPTOMYCIN ACTIVITY TESTED AGAINST 35,058 BACTERIAL STRAINS FROM HOSPITALIZED PATIENTS: SUMMARY OF A 7 YEAR SURVEILLANCE PROGRAM FOR NORTH AMERICA (2002-2008)

HS SADER, RN JONES

JMI Laboratories, North Liberty, IA, USA

ABSTRACT (REVISED)

Background: Daptomycin (DAP) is increasingly being used for treatment of skin and skin structure infection (SSSI) therapy and 5. aureus bacteremia in the USA. We report the results for 7 years of the Daptomycin ACTIV[®] Surveillance Program.

Methods: Consecutive, non-duplicate bacterial isolates (prevalence format) were collected from 2002 through 2008 from patients with documented infections in 41 medical centers in North America (NA). The isolates were collected by site of infection according to study protocols and susceptibility (5) tested against >30 antimicrobials by broth microdilution methods following CLSI guidelines. Cat' content of the broth was adjusted (50 mg/L) for testing DAP.

Results: A total of 35,058 Gram-positive (GP) isolates were evaluated. They were mainly from bacteremic (35%) and 5551 (21%). During the study period, MRSA rates increased from 45.5 to 57.3%, while resistance (R) to vancomycin (VAN) among *E faecalis* and *E faecium* increased from 2.8 and 64.9% to 6.1 and 77.1%, respectively. MRSA and VAN-R enterococci exhibited high R rates to most agents tested. DAP remained very active and no significant year-to-year variation in DAP activity was observed with any tested species. Only 35 DAP-non-5 strains (0.1%) were observed, and the vast majority (32; 91.4%) had a DAP MIC only one loog, dilution above the published 5 breakpoint.

	Curr	ulative %	No. (%) of DAP					
Organism (no. tested)	≤0.12	0.25	0.5	1	2	4	8	non-S isolates
MSSA (10,376)	5.6	79.5	99.7	99.97	100.0	-	-	3 (0.03)
MRSA (11,361)	2.2	68.6	99.1	99.91	99.99	100.0	-	10 (0.09)
CoNS (3,091)	10.0	62.5	96.0	99.7	99.94	100.0	-	10 (0.32)
E. faecalis (4,496)	1.2	6.4	49.7	94.3	99.7	99.98	100.0	1 (0.02)
E. faecium (2,875)								
Vancomycin-S (580)	1.0	2.2	6.6	32.6	83.5	99.5	100.0	3 (0.52)
Vancomycin-non-S (2,295)	0.4	1.2	5.2	30.5	84.8	99.7	100.0	6 (0.26)
β-haemolytic strep. (2,006)	76.4	98.1	100.0	-	-	-	-	0 (0.00)
Viridans group strep. (570)	31.9	64.6	92.8	99.7	100.0	-	-	
a No breakpoints have been established by CLSL or USA-EDA								

Conclusions: DAP was highly active against an extensive collection of clinically important GP pathogens. Decreased 5 to DAP remains rare after more than 5 years of clinical use in NA, and non-5 isolates (0.1%) usually have only slightly elevated DAP MICs. R to oxacillin or VAN did not adversely affect DAP activity.

INTRODUCTION

Gram-positive bacteria, especially staphylococci and enterococci, are extremely common and important pathogens causing serious infections in the hospital environment. Staphylococcus aureus, coagulase-negative staphylococci (CoNS) and enterococci are among the five most frequently isolated organisms from nosocomial bloodstream infections (BSI). These three pathogens are responsible for approximately one-half of BSI cases in North American medical centers evaluated by the SENTRY Antimicrobial Surveillance Program. The increasing occurrence of MRSA and vancomycin-resistant enterococci (VRE) prompted the development of antimicrobial agents focused against Gram-positive cocci for therapy of infections caused by these multidrug-resistant (MDR) strains.

Daptomycin is a fermentation product of *Streptomycces roseosporus* and the first lipopeptide developed for clinical use. Daptomycin inserts in the outer leaflet of the bacterial membrane, inducing the leakage of potassium which results in rapid bacterial cell death. Daptomycin is active against a wide-spectrum of Gram-positive organisms, including MDR strains of staphylococci, enterococci and streptococci. United States Food and Drug Administration (USA-FDA) approved daptomycin for the treatment of MRSA or MSSA bacteremia and right sided endocarditis at a dosage of 6mg/kg every 24 hours and for complicated skin and skin structure infections (cSSSI) using a dose of 4 mg/kg every 24.

In the present study, we evaluated the antimicrobial susceptibility patterns of clinical isolates of Gram-positive organisms collected from 41 USA medical centers in the 2002-2008 surveillance period. In addition, we compared the potency of daptomycin tested against *S. aureus, Enterococcus faecalis* and *E. faecium* collected in the 2007-2008 period with those collected in the 2002-2003 interval, i.e. before daptomycin approval by the USA-FDA

MATERIALS AND METHODS

Bacterial Isolates

As part of the Daptomycin ACTIV[™] Surveillance Program, 35,058 Gram-positive organisms were collected between January 2002 and December 2008 from 41 USA medical centers. The isolates were consecutively collected from prevalent sources of infection, including BSI, SSSI and others, according to a common surveillance design. All organisms were isolated from documented human infections and only one isolate per patient infection episode was included in the study. The isolates were identified locally and forwarded to a central monitoring laboratory (JMI Laboratories, North Liberty, Iowa, USA) for confirmation of species identification, when necessary, and reference susceptibility testing. The collection of organisms tested included: S. *aureus* (21, 737 strains), coagulase-negative staphylococci (CoNS; 3,091), *E. faecalis* (4,496), *E. faecium* (2875), *Enterococcu* spp. (236), β-haemolytic streptoccci (2,006), viridans group streptococci (570) and other less frequently isolates organisms (47).

Susceptibility test methods

Deptomycin and various comparator agents were tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods in validated, dry-form microdilution panels manufactured by TREK Diagnostics Systems (Cleveland, Ohio). The test medium was Mueller-Hinton broth adjusted to contain physiological levels of calcium (50 mg/L) when testing daptomycin. CLSI interpretive criteria were used to categorize the isolates as susceptible, intermediate and resistant. A daptomycin susceptibility breakpoint of \leq 1 µg/ml was applied for staphylococci and streptococci test interpretation, while \leq 4 µg/ml was used for the enterococcal results, as recommended by the CLSI and the USA-FDA. The following quality control organisms were concurrently tested: S. aureus ATCC 29213, E. faecalis ATCC 29213.

RESULTS

- Daptomycin was very active against 21,737 *S. aureus* isolates tested (MIC₂₉, 0.25 µg/ml and MIC₃₉, 0.5 µg/ml), and 99.9% of isolates tested were inhibited at ≤1 µg/ml. Only 13 strains showed an elevated MIC value, 12 strains with daptomycin MIC of 2 µg/ml and one with daptomycin MIC of 4 µg/ml (Table 1). Oxacillin-susceptible (MSSA) and -resistant (MRSA) *S. aureus* showed very similar daptomycin MIC distributions (Tables 1 and 2).
- During the study period, MRSA rates increased from 45.5 to 57.3% (52.3% overall; Table 2 and Figure 1) and MRSA strains exhibited high rates of resistance to many other antimicrobial agents, including clindamycin (46.1%), erythromycin (94.0%) and levofloxacin (74.6%). MSSA isolates showed higher susceptibility (290.0%) to all antimicrobial agents, except erythromycin (MG.0%, >4 µg/m) (68.9% susceptible); Table 2).
- Daptomycin MIC distributions of S. aureus collected in 2007-2008 were very similar to those of isolates collected in 2002-2003, i.e. before daptomycin approval for clinical use by the USA-FDA (Table 3).
- Among CoNS (3,091 strains; MIC₅₀, 0.25 µg/ml and MIC₅₀, 0.5 µg/ml), daptomycin MIC values ranged from 50.12 to 4 µg/ml (99.9% susceptible; Table 1). Only 10 strains with elevated MIC values were observed, eight strains with daptomycin MIC of 2 µg/ml and two strains with a reproducible daptomycin MIC of 4 µg/ml (Table 1).

Among the E. faecalis, >99.9% of vancomycin-susceptible (MICso and MICso, 1 µg/ml) and 100.0% of vancomycin-resistant (MICso, 0.5 µg/ml and MICso, 1 µg/ml) isolates were daptomycin-susceptible at ≤4 µg/ml (Table 1). Amplicillin (MICso, 2: mg/L; 97.1-99.7% susceptible) was also very active against E. faecalis, while 28.8% of vancomycin-susceptible and 69.0% of vancomycin-resistant strains showed high-level resistance to gentamicin (Table 2).

E. faecium (MICso, 2 µg/ml and MICso, 4 µg/ml; 99.5-99.7% susceptible) had daptomycin MIC values slightly higher than E. faecalis, which is consistent with premarketing surveillance. The highest daptomycin MIC result observed was 8 µg/ml (only nine strains [0.3%]; Tables 1 and 2).

- From 2004 to 2008, vancomycin resistance increased from 2.0 to 6.1% among *E. faecalis* and from 69.6 to 77.1% among *E. faecium* (Figure 1). Daptomycin and linezolid were the only compounds remaining highly active (>98% susceptible) against both vancomycinsusceptible and -resistant enterococci (Table 2).
- Daptomycin MIC distributions for *E. faecalis* and *E. faecium* (vancomycin-susceptible and -resistant strains) did not vary significantly between the 2002-2003 and 2007-2008 periods, and vancomycin resistance did not adversely affect daptomycin activity against these organisms (Tables 1 to 3).
- E. faecium, especially vancomycin-resistant strains, showed elevated rates of resistance to most comparator antimicrobial agents tested. Furthermore, 1.3% of *E. faecium* strains were resistant to linezolid and 7.7% showed reduced susceptibility (22 µg/ml) to quinupristin/dalfopristin (Table 2).
- β-haemolytic streptococci had very low daptomycin MIC values (MICs₀, ≤0.12 μg/ml; MICs₀, 0.25 μg/ml; 100.0% susceptible) and decreased susceptibility to levofloxacin was observed in 20 (1.0%) strains. Viridans group streptococci (MICs₀, 0.25 μg/ml and MICs₀, 0.5 μg/ml) generally exhibited daptomycin MIC values slightly higher (two-fold) than β-haemolytic streptococci (Tables 1 and 2).

Figure 1. Yearly rates of methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant *E. faecalis* (VREF) and *E. faecium* (VREFM).



Table 1. Daptomycin MIC distributions of Gram-positive organisms collected in USA medical centers (2002-2008).

	No. of isolates (%) inhibited at daptomycin MIC (µg/ml) of:								
Organism (no. tested)	≤0.12	0.25	0.5	1	2	4	8		
S. aureus (21,737)									
MSSA (10,376)	583(5.6)	7,667(73.9)	2,090(20.1)	33(0.3)	3(<0.1)	-	-		
MRSA (11,361)	244(2.2)	7,549(66.5)	3,469(30.5)	89(0.8)	9(<0.1)	1(<0.1)	-		
CoNS (3,091)	310(10.0)	1,621(52.4)	1,036(33.5)	114(3.7)	8(0.3)	2(<0.1)	-		
E. faecalis									
Vancomycin-susc. (4,254)	50(1.2)	215(5.1)	1,836(43.2)	1,912(45.0)	229(5.4)	11(0.3)	1(<0.1)		
Vancomycin-resistant (242)	3(1.2)	20(8.3)	111(45.9)	92(38.0)	16(6.6)	-	-		
E. faecium (2,875)									
Vancomycin-susc. (580)	6(1.0)	7(1.2)	25(4.3)	151(26.0)	295(50.9)	93(16.0)	3(0.5)		
Vancomycin-resistant (2,295)	8(0.4)	20(0.9)	91(4.0)	581(25.3)	1,247(54.3)	342(14.9)	6(0.3)		
β-haemolytic streptococci (2,006)	1,533(76.4)	435(21.7)	38(1.9)	-	-	-	-		
Viridans group streptococci (570)	182(31.9)	186(32.6)	161(28.3)	39(6.8)	2(0.4)	-	-		

Table 2. Antimicrobial activity of daptomycin and comparator agents tested against Grampositive organisms from USA medical centers.

RESULTS

MISA (10.78) Departments 22.2 Challmannical (10.78) Departments 22.2 Challmannical (10.78) Challmannical (10.78) 22.2 Challmannical (10.78) Challmannical (10.78) 22.2 Tarancychic (10.78) 21.2 Tarancychic (10.78) 21.2 MISA (11.30) 11.2 Datempoint (10.78) 22.2 Challmannical (10.78) 22.2 Challmannical (10.78) 22.2 Challmannical (10.78) 22.2 Challmannical (10.78) 22.2 Tarancychic (10.78) 22.2 Leonada (10.78) 22.2 Challmannical (10.78) 22.2	0.5 \$0.25 >2 \$0.5		
Datamyon 62.5 Christmyon 62.5 Christmyon 62.5 Christmyon 62.5 Christmyon 62.5 Lineadd 62.6 Lineadd 62.6 Lineadd 62.6 Datamyon 62.5 Christmyon 62.5 Christmyon 62.2 Christmyon 62.2 <td>0.5 \$0.25 >2 \$0.5</td> <td></td> <td></td>	0.5 \$0.25 >2 \$0.5		
Cindangon 22 Cindangon 22 Farangola 22 Farangola 22 Tarangola 2 Millad (1:37) 1 Detempon 0:23 Contage 2 Tarangola 2 Tarangola 2 Tarangola 2 Contage 2 </td <td>\$0.25 >2 \$0.5</td> <td>\$0.12 - 2</td> <td>>99.9 / -</td>	\$0.25 >2 \$0.5	\$0.12 - 2	>99.9 / -
Eryfnenycin 212 Londobia 212 Londobia 212 Londobia 212 Londobia 212 Londobia 212 Tarepsyche 212 Diadpatypia 212	>2 \$0.5	\$0.25 - >2	94.4 / 5.4
Leokascin 25.5 Leokascin 25.5 Leokascin 25.5 ThePistAC* 25.5 Vancomyon 15.5 Leokascin 25.5 Particular	\$0.5	s0.25 - >2	68.9 / 30.3
Lasado 2 Lasado 2 Turentado 2 Turentado 2 Vacanoyon 1 Billa (113) 2 Datamano 2 Datamano 2 Leonaca 2 Leonaca 2 Leonaca 2 Leonaca 2 Leonaca 2 Leonaca 2 Call (113) 2 Call (113		\$0.5 - >4	91.4 / 8.0
The PinAce 2 Variacanyon 2 MESA (13.37) 1 MESA (13.37) 2 Datebringen 2.52 El promotion 2-2 Landottaca 2 Tabelance 2 Landottaca 2 Tabelance 2 Landottaca 2 Tabelance 2 Landottaca 2 Datebringen 2.2 Containyon 2 Containyon 2.2 Enformacia 4.2 Containyon 2.2 Enformacia 4.2 Containyon 2.2 Enformacia 4.2 Containyon 1 Containyon 1 Containyon 1 Containyon 1 Containyon 1 Databanyon 1 Databanyon 1 Databanyon 1 Containson (FL) 1 Lacada	2	0.25 - 4	100.0 / -
Varcanopon 1 Varcanopon 2 Determycin 0.25 Determycin 0.22 Determycin 0.22 Determycin 0.22 Determycin 0.22 Determycin 0.22 Leodobarin 0.22 Determycin 0.22 Leodobarin 0.24 Varcanopics maceptatis (4.26) 1 Determycin 0.22 Determycin 0.22 Determycin 0.22 Determycin 0.22 Determycin 0.22 Determycin 0.25 Determycin 0.25 Deterenycin<	54 c0.6	54-20 (05-32)	96.273.2
HBSA (1,34)	1	s0.5 - 2 s0.12 - 2	100.0 / 0.0
Datempon 0.25 Cindanyon 0.25 Entranyon 0.25 Entranyon 0.25 Entranyon 0.25 Entranyon 0.25 Lineadd 1 Dolladinyon 0.25 Collis Gallon 0.25 Datempon 0.25 Collis Gallon 0.25 Collis Gallon 0.25 Collis Gallon 0.25 Collis Gallon 0.25 Entranyon 1.25 Unconsort 1.25 Collis Gallon 0.25 Collis Gallon 0.25 Collis Collis 0.25 Collis Collis 0.25 Collis Collis 0.25 Collis Collis 1.25 Entranyon 1.25 Anapicinin </td <td></td> <td></td> <td></td>			
Cindangon 212 Exploring 22 Exploring 23 Linkaski 2 Tarascine 24 Vaccompone 2 Tarascine 24 Datastine 22 Cindengrafi 23 Cindengrafi 24 Lincaski 1 Tarascifica 24 Lincaski 1 Tarascifica 24 Lincaski 25 Contamics 1 Datasting 25 Contamics 1 Datasting 25 Contamics 1 Datasting 26 Contamics 1 Datasting 27 Contamics 27 </td <td>0.5</td> <td>\$0.12 - 4</td> <td>99.9/-</td>	0.5	\$0.12 - 4	99.9/-
Enformação 2-2 Lecohazado 3-4 Lacohazado 4-4 Tarenadore 4-5 Tarenadore 4-5 Tarenadore 4-5 Tarenadore 1 Colicitadion 1 Colicitadion 2-2 Enformação 2-2 Enformação 2-2 Colicitadion 1 Tarenadore 2-2 Enformaçõite	>2	\$0.25 - >2	53.7 / 46.1
Leokaszán 44 Liszaszá 4 Liszaszá	>2	\$0.25 - >2	5.7 / 94.0
Linaxid 2 Linaxid 2 Texape,rine 4.4 Locols 0.87) 1 Determy,cin 0.25 Cols 0.87) 2 Locols 0.87) 2 Locols 0.87 2 Constance 1.87 2 Constance 1.87 1 Linaxid 1 Linaxid 1 Despective 2 Constance 1.87 2 Constance 1.87 2 Constance 1.87 2 Constance 1.87 2 Consta	>4	s0.5 - >4	24.0 / 74.6
Tatagolos 24 Turbisión 25 Turbisión 26 Dublishysion 0.25 Caldi Adhine 7 Dublishysion 0.25 Caldi Adhine 7 Exploration 7 Explor	2	\$0.25 ->8	99.9 / -
The BindA ^A 2.6 Chall APP 2.6 Colling APP 0.22 Chall APP 0.22	54	s4 - >8	93.9 / 5.7
Vacanopian 1 Vacanopian 2 Dackston 2 Dackston 2 Dackston 2 Experimenta 4 Tamagoria 4 Lineatida 1 Tamagoria 4 Vacanopia 2 Unatanopia 1 Anapidin 2 Vacanopia 1 Anapidin 2 Carlanding 1 Anapidin 2 Carlanding 1 Anapidin 2 Carlanding 1 Daptonych 5 Carlanding 1 Daptonych 5 Carlanding 1 Leothasach 1 Daptonych 2 Vacanopia-bassitati (24) 2 Vacanopia-bassitati (24) 2 Vacanopia-bassitati (25) 2 Daptonych 2 Carlandin (1 2 Daptonych	\$0.5	\$0.5 - \$2	97.5/2.5
Cole 3, 00%) on Cole 3, 00%) on Cole 3, 00% on Cole	1	0.25 - 4	>99.9 / 0.0
Dackson 22 Chokanyon 22 Chokanyon 22 Erytemych 22 Lonotasion 44 Lonotasion 44 Lonotasion 44 Lonotasion 44 Lonotasion 45 ThePitAM 45 Vacomych 12 Lonotasion 42 Lonotasion 1 Angolin 22 Erytemych 25 Contaneons(H) 10 Contaneons(H) 12 Conotasettas(H) 12			
Concellent 2 Concellent 2 Concellent 2 Explortungin 2 Landadd 4 Linadd 5 Thifeibald 2 Ephennych 1 Angolin 2 Charbaptin 1 Daptonych 1 Linazadd 1 Daptonych 1 Linazadd 1 Daptonych 1	0.5	\$0.12 - 4	99.7/-
Landmann (1) Landmann (1) La	>2	50.25 ->2	21.5 / 78.5
rementyon 22 rementyon 22 rementyon 22 rementyon 24 remen	>2	50.25 ->2	59.7739.0
Lineado 1 Lineado 4 Tarançolino 5 Daptorych 5 Daptorych 5 Cartanetici (1/) 5 Daptorych 5 Angoldin 5 Stategorych 7 Caranetic (1/) 10 Caranetic (1/) 10 Daptorych 7 Stategorych 7 Stategorych 7 Stategorych 7 Stategorych 7 Stategorych 7 Stategorych 10	>2	\$0.25 ->2	28.4770.9
Transcrise 2 Turbritak 26 Enternico 22 Enternico 22 Enternico 22 Enternico 22 Enternico 21 Enternico 22 Enternico 22 Enternico 24 Unacomprime 22 Enternico 24 Linacold 11 Ourgenerico 24 Linacold 12 Enternico 24 Linacold 12 <td>~</td> <td>50.5 - M</td> <td>41.0/00.3</td>	~	50.5 - M	41.0/00.3
1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	28	54-28	87.1/12.2
Varcomprish aussigned (J254) 1 Varcomprish aussigned (J254) 1 Darpspärin 1 Darpspärin 2 Geransens (Hc)7 6500 Leorbacker 1 Darpspärin 2 Garansens (Hc)7 5100 Teopogen 2 Varcomprish-aussigned (AC) 2 Maccomprish-aussigned (AC) 2 <t< td=""><td></td><td>\$0.5 - 22</td><td>615/385</td></t<>		\$0.5 - 22	615/385
E besoli F E besoli F Datamani - Ascatalità (4,24) Datamani - Ascatalità (4,24) Datamani - Ascatalità (4,24) Datamani - Ascatalità (4,24) Datamani - Ascatalità (4,24) 1 Caranzia (1,17) 150 Datamani (1,17) 150	2	<0.12 - P	299.9 / 0.0
Varacompte sucception 4.2549 1 Anapolitic Departments 2 Departments 2 Contransics (Hr) 2 Decomptements 1 Interaction 1 Decomptements 1 Decontements 1	-	20. 14 - U	
Datatoria 1 Angidin 2 Eptempen 2 Eptempen 2 Eptempen 2 Extendesation 1 Lacobasation 1 Bisplaymigh (b) (f) 100 Totagate 2 Extendesation 2 <td></td> <td></td> <td></td>			
Angloin 22 Exploring 22 Generations (HC) 2500 Location 11 Bragenomics (HC) 2500 Location 12 Bragenomics 22 Vancompon-Insulated (242) 2500 Location 42 Determines 22 Bragenomics 42 Exploring 42 Bragenomics 74 Locations 74 Damagenomics 74 Damagenomics 74 Damagenomics 74 Damagenomics 74 Damagenomics 74 Damagenomics 74 Databasystic 74 Databasystic 74 Databasystic 74 Databasystic 74 Databasystic 75 Bragenomics 75 Databasystic 75 Databasystic 75 Databasystic 75 Databasystic <	1	s0.12 - 8	>99.9 / -
Enformação - 2- Guranamos (H-1) - 2- Guranamos (H-2) - 2- Bangatamyo (H-2) - 2- Bangatamyo (H-2) - 2- Danagamos (H-2) - 2- Caratamos (H-2) - 2- Guranamos (H-2) - 2- Guranamos (H-2) - 2- Guranamos (H-2) - 2- Bangatamyo (H-2) - 2- Caratamos (H-2) - 2- Bangatamyo (H-2) - 2- Caratamos (H-2) - 2- Bangatamyo (H-2) - 2- Caratamos (H-2)	52	≤2 - ≥16	99.7 / 0.3
Garansen; (H_1') 500 Lincold 1 Lincold 1 Lincold 1 Tacognio 2 Tacognio 2 Tacognio 2 Datemych-seatiart (242) 2 Datemych 5 Datemych 5 Caransen; (H_1') 100 Loncold 1 Datemych 5 Caransen; (H_1') 100 Tacognio 2 Macomych-Institut (200) 200 Tacognion 4 Vacomych-Institut (200) 200 Tacognion 2 Argenion 2 Batering 2 Garansen; (H_1') 400 Vacomych-Institut (200) 1 Tacognin 2 Vacomych-Institut (200) 2 Argenion 2 Argenion 2 Argenion 2 Argenion 2 Argenion 2 <tr< td=""><td>>2</td><td>s0.25 - >2</td><td>9.1/61.7</td></tr<>	>2	s0.25 - >2	9.1/61.7
Leokaschi 1 Lineadd 1 Turneyd Frifield 1 Turneyd Frifield 1 Datemark (12) 2 Datemark (12) 2 Datemark (12) 2 Datemark (14) 1 Datemark (>1000	s500->1000	71.2 / 28.8
Linasid 1 Linasi	>4	s0.5 - >4	65.0 / 34.6
Bingstomych (K,f) £100 Taccapiane 120 Taccapiane 120 Taccapiane 120 Taccapiane 120 Taccapiane 120 Taccapiane 120 Carbancier (Hz) 100 Laccapiane 120 Carbancier (Hz) 100 Laccapiane 120 Taccapiane 200 Taccapiane 200 Taccapiane 200 Taccapiane 200 Datestruych 120 Datestruych 200 Taccapiane 200 Taccapiane 200 Datestruych 200 Taccapiane 20	2	\$0.25 ->8	99.9 / 0.1
Teception 2 Vacamprois-instantia (124) Vacamprois-instantia (124) Vacamprois-instantia (124) 2 Anargialm 2 Carstances (147) 420 Lineation 141 Composition (147) 420 Strapture (147) 420 Teampoint -2 Strapture (147) 200 Teampoint -2 Strapture (147) 200 Teampoint -2 Anardialm -10 Anardialm -2 Cartanocycle acception (247) 200 Cartanocycle acception (247) -2 Cartanocycle acception (247) -200 Tecoprism -2 Ca	>2000	≤1000 - >2000	75.0 / 25.0
Vaccomprisesistant (242) Destroyment (242) Experiment (247) Experiment (247) Exp	\$2	\$2-4	100.0 / 0.0
Dateborycin 6.5 Angeldin 5.5 Angeldin 5.6 Angeldin 5.6 Caranacces (H) 1.00 Lacoback 1.4 Lacoback 1.4 Database 1.00 Brepterspring (H) 1.00 Description 1.4 Exacuta 1.00 Tocoparis 2.4 Angeldin 7.6 Exploration (F) 2.00 Angeldin 7.6 Valoration (F) 2.0 Angeldin 7.6 Angeldin 1.2 Angeldin 1.2 Angeldin 1.2 Angeldin 1.2 Angeldin 1.2 Angeldin 1.2 Angeldin 1.4 Lacoda			
Angolin 22 Explorange (14' 20) Explorange (14' 20) Leotobracin (14' 20) Leotobracin (14' 20) Leotobracin (14' 20) Leotobracin (14' 20) Electrony (1	\$0.06 - 2	100.0 / -
Lingtonych (* 2007) Lineadda (* 2007) Lineadda (* 2007) Strategier (*	52	\$2->16	97.1/2.9
ueumanie (HC) >100 Lineada 1 Carno (Lineada) 1 Carno (Lineada) 1 Carno (Lineada) 1 Carno (Lineada) 1 Straptomych (Lineada) 1 Anapolin -1 Anapolin -1 Anapolin -1 Carno (Lineada) -1<	>2	\$0.25 - >2	0.8/95.5
Lessadi 1 Longristification 2-2 Braptamyon (HL) 2-20 Tacoplanin 3-6 Tacoplanin 3-6 Datopristification 3-6 E faccia -200 Datopristification 3-6 E faccia -16 E phromych 2-2 Angristification -16 Experimention 2-2 Caratascin (HL) 10 Displanych 2-2 Angristificationality 1 Displanych 2-2 Angristificationality 1 Displanych 2-2 Angristificationality 1 Displanych 2-2 Angristificationality 2-2 Angristificationality 2-3 Linearidi 1 Displanych 2-2 Christificationality 1 Displanych 2-2 Christificationality 1 Displanych 2-2 Christificationality <td>~1000</td> <td>5500 ->1000</td> <td>17/071</td>	~1000	5500 ->1000	17/071
Description in the second statistication 2 Brandsmarks (n) (n) 20 Brandsmarks (n) 10 Cancell 2 Market (n) 2 Anapidalin 7 Exploring (n) 2 Anapidalin 7 Lucoblastic 2 Anapidalin 7 Lucoblastic 2 Anapidalin 1 Contransition (n) 1 Marcompolin Schull 1 Marcompolin Schull 2 Anapidalin 1 Marcompolin Schull 1 Lineadidin 1 Marcompolin Schull 1 Marcompolin Schu	24	1->4	1.7/97.1
americanismistration 30 americanismistration 30 Tecogradio 30 Tecogradio 30 Tecogradio 30 Destropping 30 Destropping 31 Election 44 Election 45 Election 42 Vacamorich-satisfication (1) 15 Straptomych (1) 450 Election 45 Election<	2	0.0 - 40	17/070
Tacsopie -200 Tacsopie -200 Vancomych susceptie (850) Datemych Datemych -200 Angichan -16 Carlanisch -16 Carlanisch -16 Carlanisch -16 Carlanisch -16 Carlanischlägsdah 1 Datemych -22 Angichin -10 Datemychnestater (2205) Datemychnestater (2205) Datemychnestater (2205) -11 Datemychnestater (2205) -12 Angichin -5 Stapptomychnestater (2005) -16 Leordmach 1 Datemych stapptomych 22 Okonsen 62 Okonsen 62 Christen 62 Christen 62 Christen 62 Christen 62 Leordmach 1 Pausting 62 Lordmach 62 Lordmach 62	~2	50.25 - #2	1.7 / 97.9/
E Reaction	>16	\$2->16	43.0 / 55.0
Vaccompres suscepting (80) Deptompting 2 Angiolin -16 Exploring 24 Exploring 24 Exploring 24 Exploring 1 During information 1 During information 1 During information 1 During information 2 Vaccompton restant (2.295) 2 Deptompton 2 Angiolin -16 Exploring 2 Angiolin -16 Suspering (1) 25 Suspering (1) 25 Suspering (1) 10 During information 12 Lecolinacia 1 During information 22 Coldinacia 22 Coldinacia 23 Coldinacia 24 Lineadid 21 Londonacia 22 Londonacia 23 Lineadid 21 Lineadid 21 <td></td> <td></td> <td></td>			
Datatorycin 2 Angician 12 Angician 12 Erytennych 2 Erytennych 2 Landbraken 4 Lanschl 1 OutroprinterSafter/Life 1 Tracegolia 2 Datorych 12 Datorych 2 Caranychine 2 Datorych 3 Caranychine 4 Lassold 5 Expremych 4 Lassold 5 Expremych 4 Lassold 5 Expremych 4 Lassold 5 Expremych 5 Expremych 5 Expremych 5 Expremych 5 Expremych 6 Expremych 6 Expremych 6 Expremych 6 Expremych 6 Expremych 6			
Angizin -115 Explorances (61,7 200 Carstances (61,7 200 Unavaid 1 Damping (11,10) 1	4	s0.12 - 8	99.5/-
Enfremçin 22 Enfremçin (Fr.) 555 Leonación 4 Leonación 4 Leonación 4 Leonación 4 Leonación 4 Bragenyce intel (2359) Datomyce institut (2359) Datomyce intel (2359) Datomyce intel (2359) Datomyce intel (2359) Contación 4 Datomyce intel (2350) Contación 4 Leonación 4 Leonación 4 Datomyce intel (2350) Contación 4 Datomyce intel (2350) Datomyce intel	>16	≤2 - ≥16	23.1/76.9
Gertamine (H) 550 Levoltascio 14 Levoltascio 14 Darsopuncisalitycalion 1 Birglatorych (H) 10 Teocoganic 2 Aradiola 2 Aradiola 1 Birglatorych (H) 20 Aradiola 2 Aradiola 4 Levolutani 4 Darsopulationality (H) 500 Teocoganic 4.0 Darsopulationality (H) 500 Teocoganic 4.0 Darsopulationality (H) 500 Teocoganic 4.0 Darsopulationality (H) 5.0 Teocoganic 4.0 Darsopulationality (H) 5.00 Darsopulationality (H) 5.00 Collidamyon 6.2 Collidamyon 6.2 Collidamyon 6.2 Lineaxida 1.1 Parality (H) 5.0 Teocoganic 1.0 Lineaxida 1.0	>2	\$0.25 ->2	9.3 / 75.3
Lendmach +4 Lineadd 1 Line	>1000	s500->1000	86.9 / 13.1
Linacidi 1 Outropristriculturality 1 Dampristriculturality 1 Tracospila 2 Datamortistriculturality 2 Datamortistriculturality 3 Datamortistriculturality 3 Datamortistriculturality 3 Datamortistriculturality 3 Datamortistriculturality 3 Caranzosci (16) 4 Licacida 4 Districulturality 5 Districulturality 5 Districulturality 4 Districulturality 4 Districulturality 5 Districulturality 5 Districulturality 6 Districulturality	>4	\$0.5 - >4	21.9 / 72.8
Our-projection 1 Durpativity-information 1 Transport 2 Durpativity-information 2 Angletistic 2 Displantivity-information 2 Angletistic 2 Angletistic 2 Angletistic 2 Lineardia 1 Displantivity-information 5 Straptativity-information 5 Displantivity-information 6.2 Christense 6.2	2	0.5 ->8	99.1/0.9
Bingtonych (KL)* £100 Tacoglann £2 Varing Schwähler (2,255) 2 Angräfin 2 Angräfin 5 Eryffernych 2 Gertamens (Hu)* 55 Levotknackn 1 Eryffernych 52 Jamer (Hu)* 55 Binghermych (Hu)* 520 Tecoplann 51 Digtothych 62 Cerhansch (Hu)* 50 Elyfernych 62 Elyfernych 62 Levotknach 10 Digtothych 62 Luchthacknach 63 Luchthacknach 63 Luchthacknach 63 Luchthacknach 63 Luchthacknach 63 Tetracycline 6201	>2	\$0.25 ->2	76.4 / 10.3
Teocoguine 22 Vacontrol-in-Vacular (2.206) 2 Anardoni -16 Exploration -26 Liscolutario -16 Exploration -26 Damagnation -26 Collindumyon -26.22 Exploration -26.20 Collindumyon -26.20 Lineasida -11 Panalini -26.00	>2000	≤1000 - >2000	66.8/33.2
Vaccomprisesitated (2,295) Datatonycon 1 Enformación 1 Enformación 1 Enformación 1 Caranancion (Hr.) 6500 Levoltascan 1 Daramación (Hr.) 55 Tercognamic 1 Patamonico (El composito) 620 Carlanciano 62 Cinclamación 62 Cinclamación 62 Cinclamación 63 Lancadid 63 Lineación 63 Lineación 63 Lineación 63 Taracyclinio 64	\$2	s2-4	100.0 / 0.0
Datatonycin 2 Angelatin 1-2 Angelatin 1-2 Angelatin 1-4 Linscold 500 Linscold 500 Brandmych (M) 1-5 Brandmych (M) 1-5 Brandmych (M) 1-5 Brandmych (M) 1-20 Distantych (M) 1-20 Christewan 6.20 Christewan 6.20 Linscold 6.20 Linscold 6.20 Linscold 6.20 Linscold 6.20 Tarbacychine 6.20 Linscold 6.20 Linscold 6.20 Tarbacychine 6.20 Linscold 6.20 Tarbacychine 6.20 Linscold 6.20 Linscold 6.20 Tarbacychine 6.20			
Antpoln -16 Exploring, of 1 -20 Exploring, of 1 -20 Exploring, of 1 -20 Leorobacan -4 Luneadd 1 Garpanny, of 1 -05 Stopptomy, of 1 -05 Stopptomy, of 1 -06 Jamobild, stopptomy, of 1 -06 Datatong on 62 Cindeangen 62 Cindeangen 62 Licobakan 1 Paracijne 62 Licobakan 1 Prancijne 62	4	\$0.06 - 8	99.7/-
c preventycni 22 Centramicni († 2 Centramicni († 2 Centramicni († 2 Centramicni († 2 Centramicni († 2 Centramicni († 2 Strategalani († 2 Strategalani († 2 Centramicni († 2 Centramicn	>16	\$1 -> 16	0.7/99.3
uementin() (fr.) 250 Lineado 14 Lineado 1 Stephonyen (http://stephone.instituced) 1 Stephonyen (http://stephone.instituced) 1 Datarohyte improvement (http://stephone.instituced) 10 Datarohyte improvement (http://stephone.instituced) 10 Datarohyte improvement (http://stephone.instituced) 10 Cilindanyon 62 Expritromycin 62 Lineadod 1 Pencinith 2011 Tetracycline 50	>2	50.25 ->2	1.8/94.6
Lineadd 1 Lineadd 1 Gungarialisalarynaid 5 Sibeptanych (Lf. 2007) Taicapain 21 Diadargen 21 Diadargen 21 Cindanych 21 Cindanych 21 Cindanych 21 Cindanych 21 Cindanych 21 Lieototach 21 Lineadd 1 Pencilin 20	>1000	2500 ->1000	67.8732.2
Linux 2013 mislafoptision 1 1 20	~	50.00 - 44	0.3/99.0
Bitspunycie (k1,5) 200 Tałczyławia >200 płanodyść atylokocci (2,008) 201 Daptomolyć atylokocci (2,008) 202 Chłkatnych 202 Chłkatnych 202 Lawicki 202 Lawicki 202 Lawicki 202 Lawicki 1 Parcielin 200 Tałczyche 54	1	50.25 - >2	96.3/1.3
Paterning and approximation >16 Paterning a straptococi (2,006) Deptomycin Daptomycin 512 Cinidamycin 512 Environycin 522 Environycin 522 Levodoxacin 40 Unacalid 1 Periolin 50 Tatacycline 54	>2000	≤1000 - >2000	38.2/61.8
β-haemolytic streptococci (2,006) Daptomycin 20.1: Cethiaxone 20.2: Citidaamycin 20.22: Erythromycin 20.22: Levotloxacin 20.5 Linecold 1 Pencillin 20.01 Tetracycline 54	>16	\$2 -> 16	6.6 / 82.5
Daptomycin 20.1; Ceffisianore 30.2; Clindamycin 30.2; Eryffromycin 30.2; Levoftoxacin 20.5; Lincoldi 1 Penicilin 20.01; Tetracycline 54			
Ceffriance 50.2 Cindamycin 50.2 Enytenomycin 50.2 Levofloxacin 50.5 Linacold 1 Pencillin 50.00 Tetracycline 54	0.25	s0.12 - 0.5	100.0 / -
Clindamycin s0.2: Erythomycin s0.2: Levofloxacin s0.5 Linozold 1 Penicilin s0.01 Tetracycline s4	\$0.25	\$0.25 - 2	99.9 / -
Erythromycin \$0.25 Lävedhavacin \$0.55 Linezolid 1 Panicilin \$0.01 Tetracycline \$4	1	\$0.25 - >2	89.6 / 10.1
Levofloxacin s0.5 Linezolid 1 Penicilin s0.01 Tetracycline s4	>2	s0.25 - >2	74.8 / 24.9
Linezolid 1 Penicilin s0.01 Tetracycline s4	1	s0.5 - >4	99.0 / 0.8
Penicilin s0.01 Tetracycine s4	1	\$0.06 - 2	100.0 / -
Tetracycline 54	0.06	\$0.015 - 0.12	100.0 / -
Minister and American Street (1970)	>8	s4 - >8	46.3 / 49.5
vinuens group streptococci (570)			
Daptomycin 0.25	0.5	\$0.12 - 2	99.7/-
Ceftriaxone s0.25	1	\$0.25 - 32	93.9 / 2.8
Clindamycin s0.25	\$0.25	\$0.25 ->2	91.4 / 7.9
Erythromycin 0.5	>2	\$0.25 ->2	48.9 / 48.9
Levofloxacin 1	2	\$0.5 - >4	91.6 / 7.2
Linezolid 1	1	\$0.25 - 2	100.0 / -
Penicilin 0.06	1	\$0.015 - 32	72.6 / 4.9
Tetracycline s4	>8	s4 - >8	63.2 / 28.8

HELIO S. SADER, MD, PHD, JMI LABORATORIES 345 BEAVER KREEK CENTRE, SUITE A NORTH LIBERTY, IOWA 52317 PHONE: 1 (319) 665-3370 FAX: 1 (319) 665-3371 EMAIL: HELIO-SADER@JMILABS.COM

Table 3. Frequency of occurrence of daptomycin MIC values for the organisms tested.

	No. of isolates (%) inhibited at MIC (µg/ml) of:								
Organism (no. total)	≤0.06	0.12	0.25	0.5	1	2	4	8	
S. aureus									
Oxacillin-susceptible									
2007-2008 (3,563)	5 (0.1)	207 (5.8)	2,769 (77.7)	572 (16.1)	10 (0.3)	-	-	-	
2002-2003 (1,879)	2 (0.1)	123 (6.5)	1,440 (76.6)	305 (16.3)	6 (0.3)	1 (<0.1)	-	-	
Oxacillin-resistant									
2007-2008 (4,514)	2 (<0.1)	106 (2.4)	3,171 (70.3)	1,189 (26.3)	38 (0.8)	7 (0.2)	1 (<0.1)	-	
2002-2003 (1,598)	1 (0.1)	32 (2.0)	1,043 (65.3)	512 (32.0)	10 (0.6)	-	-	-	
Enterococcus faecalis									
2007-2008 (1,401)	5 (0.4)	9 (0.6)	48 (3.4)	484 (34.6)	726 (51.8)	125 (8.9)	4 (0.3)	-	
2002-2003 (981)	2 (0.2)	10 (1.0)	87 (8.9)	478 (48.7)	367 (37.1)	38 (3.9)	2 (0.2)	-	
Enterococcus faecium									
vancomycin-susceptible									
2007-2008 (203)	0 (0.0)	2 (1.0)	4 (2.0)	7 (3.5)	57 (28.1)	117 (57.6)	14 (6.9)	2 (1.0)	
2002-2003 (93)	0 (0.0)	2 (2.2)	1 (1.1)	1 (1.1)	12 (12.9)	52 (55.9)	24 (25.8)	1 (1.1)	
vancomycin-resistant									
2007-2008 (640)	2 (0.3)	2 (0.3)	10 (1.6)	14 (2.2)	204 (31.9)	376 (58.8)	30 (4.7)	2 (0.3)	
2002-2003 (949)	1 (0.1)	3 (0.3)	5 (0.5)	29 (3.1)	153 (16.2)	535 (56.4)	219 (23.1)	4 (0.4)	
- = No isolate with this MIC value									

CONCLUSIONS

- Daptomycin was highly active against S. aureus. Only 13 of 21,737 (0.06%) isolates tested were found to have daptomycin MIC values greater than 1 µg/ml (non-susceptible), with no significant trend towards higher MIC results over time.
- Resistance to vancomycin or quinupristin/dalfopristin or linezolid or oxacillin <u>did not</u> compromise daptomycin potency against staphylococci or enterococci.
- Daptomycin non-susceptibility remains extremely rare after many years of clinical use, indicating that the emergence of non-susceptibility is very low in USA medical centers.

REFERENCES

- Clinical and Laboratory Standards Institute (2009a) M07-A8, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition. Wayne, PA: CLSI.
- Clinical and Laboratory Standards Institute (2009b) M100-S19, Performance standards for antimicrobial susceptibility testing, 19th informational supplement. Wayne, PA: CLSI.
- Cubicin Package Insert (2009) Available at http://www.cubicin.com/pdf/PrescribingInformation.pdf; accessed on June 2009.
- Leclercq R (2009) Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci Clin Microbiol Infect 15:224-231.
- Levine DP (2008) Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 62 (Suppl 3):iii35-39.
- 6. Livermore LM (2008) Future directions with daptomycin. J Antimicrob Chemother 62 (suppl 3): iii41-49.
- Pfaller MA, Sader HS, Jones RN (2007) Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). *Diagn Microbiol Infect Dis* 57:459-65.
- 8. Rice LB (2006) Antimicrobial resistance in gram-positive bacteria. Am J Med 119 (Suppl 1):S11-19.
- Sader HS, Fey PD, Fish DN, Limaye A, Pankey G, Rahal J, Rydak M, Snydman D, Steed L, Waltes K, Jones RN (2009) Evaluation of vancomycin and daptomycin potency trends (MIC) creep? against methicilin-resistant Staphylococcus aureus collected in nine United States medical centers over five years (2002- 2006). Antimicrob Agents Chemother 53(10): 4127-4132.